药械指南

订阅

MedSci主页 / 所有栏目 / 药械指南

化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）

2021-07-02 国家药品监督管理局药品审评中心（CDE） CDE

创新药物创新药

为鼓励创新药研发和申报，提高申请人和监管机构沟通交流的质量与效率，加快创新药上市进程，我中心组织制订了《化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）》。

中文标题：

化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2021-07-02

简要介绍：

为鼓励创新药研发和申报，提高申请人和监管机构沟通交流的质量与效率，加快创新药上市进程，我中心组织制订了《化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）》。
       我们诚挚地欢迎社会各界对征求意见稿提出宝贵意见和建议，并及时反馈给我们，以便后续完善。征求意见时限为自发布之日起一个月。
       您的反馈意见请发到以下联系人的邮箱：
       联系人：王亚静、牛寒冬
       联系方式：wangyajing@cde.org.cn、niuhd@cde.org.cn
       感谢您的参与和大力支持。
                                                                                                                           国家药品监督管理局药品审评中心
                                                                                                                                         2021年7月2日

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d96811c002125654, title=化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）, enTitle=, guiderFrom=CDE, authorId=0, author=, summary=为鼓励创新药研发和申报，提高申请人和监管机构沟通交流的质量与效率，加快创新药上市进程，我中心组织制订了《化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）》。, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心（CDE）, associationIntro=国家药品监督管理局药品审评中心（CDE）, copyright=0, guiderPublishedTime=Fri Jul 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">为鼓励创新药研发和申报，提高申请人和监管机构沟通交流的质量与效率，加快创新药上市进程，我中心组织制订了《化学药品创新药上市申请前会议药学共性问题相关技术要求（征求意见稿）》。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 我们诚挚地欢迎社会各界对征求意见稿提出宝贵意见和建议，并及时反馈给我们，以便后续完善。征求意见时限为自发布之日起一个月。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 您的反馈意见请发到以下联系人的邮箱：</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 联系人：王亚静、牛寒冬</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 联系方式：wangyajing@cde.org.cn、niuhd@cde.org.cn</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 感谢您的参与和大力支持。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 国家药品监督管理局药品审评中心</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2021年7月2日</span></p>, tagList=[TagDto(tagId=10749, tagName=创新药物), TagDto(tagId=16924, tagName=创新药)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11745, appHits=31, showAppHits=0, pcHits=576, showPcHits=11714, likes=0, shares=12, comments=7, approvalStatus=1, publishedTime=Sun Jul 04 22:21:17 CST 2021, publishedTimeString=2021-07-02, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sun Jul 04 22:21:14 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 04:01:36 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=997639, encodeId=1e5199e6393c, content=理学药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 08 18:16:30 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996704, encodeId=ecc9996e0482, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:19:22 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996463, encodeId=bae499646395, content=确实有很多问题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfac5541944, createdName=iris6898, createdTime=Mon Jul 05 16:59:13 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996425, encodeId=76c799642504, content=需要时用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74b81761387, createdName=ms3882304424310386, createdTime=Mon Jul 05 14:49:16 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996399, encodeId=9428996399fb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d9b5541675, createdName=ms8000001471478848, createdTime=Mon Jul 05 13:59:24 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-08 ms3000001999514966

    理学药物

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=997639, encodeId=1e5199e6393c, content=理学药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 08 18:16:30 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996704, encodeId=ecc9996e0482, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:19:22 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996463, encodeId=bae499646395, content=确实有很多问题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfac5541944, createdName=iris6898, createdTime=Mon Jul 05 16:59:13 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996425, encodeId=76c799642504, content=需要时用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74b81761387, createdName=ms3882304424310386, createdTime=Mon Jul 05 14:49:16 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996399, encodeId=9428996399fb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d9b5541675, createdName=ms8000001471478848, createdTime=Mon Jul 05 13:59:24 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-06 ms3000001999514966

    理学主题

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=997639, encodeId=1e5199e6393c, content=理学药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 08 18:16:30 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996704, encodeId=ecc9996e0482, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:19:22 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996463, encodeId=bae499646395, content=确实有很多问题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfac5541944, createdName=iris6898, createdTime=Mon Jul 05 16:59:13 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996425, encodeId=76c799642504, content=需要时用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74b81761387, createdName=ms3882304424310386, createdTime=Mon Jul 05 14:49:16 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996399, encodeId=9428996399fb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d9b5541675, createdName=ms8000001471478848, createdTime=Mon Jul 05 13:59:24 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-05 iris6898

    确实有很多问题

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=997639, encodeId=1e5199e6393c, content=理学药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 08 18:16:30 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996704, encodeId=ecc9996e0482, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:19:22 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996463, encodeId=bae499646395, content=确实有很多问题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfac5541944, createdName=iris6898, createdTime=Mon Jul 05 16:59:13 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996425, encodeId=76c799642504, content=需要时用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74b81761387, createdName=ms3882304424310386, createdTime=Mon Jul 05 14:49:16 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996399, encodeId=9428996399fb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d9b5541675, createdName=ms8000001471478848, createdTime=Mon Jul 05 13:59:24 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-05 ms3882304424310386

    需要时用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=997639, encodeId=1e5199e6393c, content=理学药物, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 08 18:16:30 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996704, encodeId=ecc9996e0482, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:19:22 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996463, encodeId=bae499646395, content=确实有很多问题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfac5541944, createdName=iris6898, createdTime=Mon Jul 05 16:59:13 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996425, encodeId=76c799642504, content=需要时用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74b81761387, createdName=ms3882304424310386, createdTime=Mon Jul 05 14:49:16 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996399, encodeId=9428996399fb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d9b5541675, createdName=ms8000001471478848, createdTime=Mon Jul 05 13:59:24 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-05 ms8000001471478848

    学习了

    0

相关指南

药品附条件批准上市技术指导原则（试行）

国家药品监督管理局药品审评中心（CDE） · 2020-11-26